Sjögren's syndrome

Quintessence International

Volumn 30, Issue 10, 1999, Pages 689-699

  Rhodus, Nelson L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PILOCARPINE; SALIVA SUBSTITUTE; WETTING AGENT;

ADULT; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGY; MALE; MINOR SALIVA GLAND; PATHOLOGY; REVIEW; SALIVA; SECRETION; SIALOGRAPHY; SJOEGREN SYNDROME;

ADULT; FEMALE; HUMANS; MALE; PILOCARPINE; SALIVA; SALIVA, ARTIFICIAL; SALIVARY GLANDS, MINOR; SIALOGRAPHY; SJOGREN'S SYNDROME; WETTING AGENTS;

EID: 0033206326     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (77)

1. Moutsopoulos HM, Chused TM, Mann D, Klippel JH, Fauci AS, Frank MM, Lawley TJ, Hamburger MI. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med 1979;66:733-736.
2. Fox RI. Clinical features, pathogenesis, and treatment of Sjögren's syndrome. Curr Opin Rheum 1996;8:438-445.
3. Rhodus NL. Diagnosis and management of the patient with Sjögren's syndrome. Compend Contin Educ Dent 1987;8: 578-593.
4. Fox RI. Sjögren's syndrome. Controversies and progress. Clin Lab Med 1997;17:431-444.
5. Atkinson JC, Fox PC. Sjögren's syndrome: Oral and dental considerations. J Am Dent Assoc 1993;124:74-83.
6. Fox RI, Howell FV, Bone RC, Michelson P. Primary Sjögren's syndrome: Clinical and immunopathologic features. Semin Arthritis Rheum 1984;14:77-105.
7. Sjögren's syndrome. WHO Technical Report, serial 816: Rheumatic Diseases. Geneva: World Health Organization, 1992:21.
8. Jacobsson LTH, Manthorpe R. Die epidemilogie des Sjögren's syndrome. Rheumatol Eur 1995;24:46-47.
9. Fitzler MJ, Pauls JD, Kinsella TD. Antinuclear, anticytoplasmic and anti-Sjögren's syndrome antigen A(SS-A-Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1995;36:120-128.
10. FDA approves Salagen for Sjögren's syndrome. Sjögren's Digest 1998;8(3):1-3.
11. Zhang NZ, Shi CS, Yoa QP, Pan QX, Wang LL, Wen ZX, Li XC, Dong Y. The prevalence of Sjögren's syndrome in China. J Rheumatol 1995;22:659-661.
12. Koopman WJ. Arthritis and Related Conditions. Baltimore, MD: Williams and Wilkins, 1997:chapter 2.
13. Ostuni PA, Ianniello A, Sfriso P, Mazzila G, Andretta M, Gambari PF. Juvenile onset of primary Sjögren's syndrome: Report of ten cases. Clin Exp Rheumatol 1996;14: 689-693.
14. Rhodus NL, Colby S, Moller K, Bereuter J. Quantitative assessment of dysphagia in patients with primary and secondary Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:305-310.
15. Rhodus NL. Glossodynia and xerostomia associated with autoimmune diseases. Ear Nose Throat J 1989;68: 791-796.
16. Daniels TE, Fox PC. Salivary and oral components of Sjögren's syndrome. Rheum Dis Clin North Am 1992;8: 571-589.
17. Daniels TE, Silverman S, Michalski JP, Greenspan JS, Sylvester RA. The oral component of Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1975;39:875-885.
18. Moutsopoulos HM, Tzioufas AG, Bai MK, Papadopoulos NM. Association of serum IgM kappa monoclanality in patients with Sjögren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial salivary glands. Ann Rheum Dis 1990;49:929-931.
19. Najera M, Al-Hashimi I, Plemons J, Rivera-Hildago F, Rees TD, Haghighat N, Wright JM. Prevalence of periodontal disease in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:453-457.
20. Rhodus NL, Michalowicz B. Candida, GCF and periodontal disease in patients with primary Sjögren's syndrome [abstract 1988]. J Dent Res 1998;77:120.
21. Rhodus NL. Qualitative nutritional intake analysis of older adults with Sjögren's syndrome. Gerodontology 1988;7:61-69.
22. Mandel ID, Wotman S. The salivary secretions in health and disease. Oral Sci Rev 1976;8:25-47.
23. Tapper-Jones L, Aldred M, Walker DM. Prevalence and intraoral distribution of Candida albicans in Sjögren's syndrome. J Clin Pathol 1980;33:282-287.
24. MacFarlane TW. The oral ecology of patients with severe Sjögren's syndrome. Microbios 1984;41:99-106.
25. Hernandez YL, Daniels TE. Oral candidiasis in Sjögren's syndrome: Prevalence, clinical correlations and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1989; 68:324-329.
26. Rhodus NL, Liljemark WF, Bloomquist C, Bereuter J. Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride. Quintessence Int 1998;29:705-710.
27. Manthorpe R, Oxholm P, Pruase JU, Shiodt M. The Copenhagen Criteria for diagnosis of Sjögren's syndrome. Scand J Rheumatol 1986;61:19-21.
28. Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am 1994;20:391-407.
29. Skopouli FN, Drosos AA, Papaioannou T, Moutsopoulos HM. Preliminary criteria for diagnosis of Sjögren's syndrome. Scand J Rheumatol Suppl 1986;61:22-25.
30. Homma M, et al. Scand J Rheumatol Suppl 1986;61:26-27.
31. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis Rheum 1993;36:340-347.
32. Moutsopoulos HM, Tzioufas AG. Sjögren's syndrome. In Klippel JH, Dieppe PA (eds). Rheumatology. St Louis: Mosby, 1994:chapter 6.
33. Gromnica-Ihle E. Sjögren's syndrome-Diagnosis and therapy. The clinical picture. Biomed Ther 1997;25(2):54-59.
34. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-156.
35. Greenspan JS, Greenspan D, Daniels T. The histopathology of Sjögren's syndrome in labial salivary gland biopsies. Oral Surg 1974;37:217-229.
36. Navazesh M, Christensen CM, Brightman VJ. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 1992;71:1363-1369.
37. Shern RJ, Fox PC, Cain JL. A method for measuring the flow from the minor salivary glands. J Dent Res 1990;69: 1146-1149.
38. Rhodus NL, Bereuter J. Oral pilocarpine HCI stimulates labial (minor) salivary gland flow in patients with primary Sjögren's syndrome. Oral Dis 1997;3:93-98.
39. Sciubba JJ. Sjögren's syndrome: Pathology, oral presentation and dental management. Compend Contin Educ Dent 1990; 15:1084-1095.
40. Ohbayashi N, Yamada I, Yoshino N, Sasaki T. Sjögren's syndrome: Comparison of assessments with MR sialography and conventional sialography. Radiology 1998;209: 683-688.
41. Daniels TE. An evaluation of salivary scintigraphy in Sjögren's syndrome. Arthritis Rheum 1979;22:809-814.
42. Mandel ID, Baurmash H. Sialochemistry in Sjögren's syndrome. Oral Surg 1976;41:182-187.
43. Stuchell RN, Mandel ID, Baurmash H. Clinical utilization of sialochemistry in Sjögren's syndrome. J Oral Pathol 1976; 13:3030-3039.
44. Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: Immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Crit Rev Oral Biol Med 1996;7:144-158.
45. Jordan RCK, Speight PM. Lymphoma in Sjögren's syndrome from histopathology to molecular pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81: 808-820.
46. Kassan S, Thomas T, Moutsopoulos HM. The increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89: 888-892.
47. Lakshminarayanan S, Waterman J, Parke A. B-cell lymphoma in patients with Sjögren's syndrome [abstract 1776]. J Rheumatol 1998;25:210.
48. Bottomley W, Rosenberg S, Alexander W, Arm R, Boozer C, Brooke R, Brown R, Cohen L, Fast T, Fischman S, Konzelman J, Little JW, Lucatorto F, Reiner A, Rhodus NL, Ross SJ. Clinician's Guide to the Management of Common Oral Lesions. New York: American Academy of Oral Medicine, 1997:4-25.
49. Little JW, Falace DA, Miller CS, Rhodus NL. Dental Management of the Medically Compromised Patient, ed 5. St Louis: Mosby, 1997:536-539.
50. Rhodus NL, Bereuter J. A clinical evaluation of Optimoist in relieving signs and symptoms of xerostomia in patients with Sjögren's syndrome [abstract 805]. J Dent Res 1997;76: 251.
51. Rhodus NL, Schuh MJ. The effectiveness of three artificial salivas in relieving xerostomia in patients with Sjögren's syndrome as assessed by the mucoprotective relativity index [abstract 1332]. J Dent Res 1991;70:460.
52. Vissink A, Schaub RMH, van Rijn LH, s'Gravenamde EJ, Panders AK, Vermey A. The efficacy of a mucin-containing artificial saliva in alleviating symptoms of xerostomia. Gerodontology 1987;6:391-407.
53. Mandel ID, Katz R. The effect of pilocarpine and a beta-adrenergic blocking agent on human saliva. Pharmacol Ther Dent 1971;1:71-82.
54. Fox PC, van der Yen PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986; 61:243-245.
55. Dawes C. The composition of human saliva secreted in response to a gustatory stimulus and pilocarpine. J Physiol 1966;183:360-368.
56. Mandel ID, Katz R, Zengo A. The effect of pharmacologic agents on salivary secretion in man. I. Pilocarpine, atropine and anticholinesterases. J Oral Ther 1967;4:192-199.
57. Hensten-Pettersen A. Biological activities in human labial and palatine secretions. Arch Oral Biol 1975;75:592-593.
58. Silverman S. Radiation effects. In Silverman S (ed). Oral Cancer. New York, American Cancer Society, 1981:67-68.
59. Greenspan D, Daniels TE. The use of pilocarpine in post-irradiation xerostomia [abstract 1319]. J Dent Res 1979;58:420.
60. Rhodus NL, Schuh MJ. The effects of pilocarpine on salivary flow in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1991;72:545-549.
61. Johnson JT, Ferreti GA, Nethery WJ, Valdez IH, Fox PC, Ng DA, Muscoplat C, Gallagher SC. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. New Engl J Med 1993;329:390-395.
62. Valdez IH, Wolff A, Atkinson JC, Mackynski A, Fox PC. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848-1851.
63. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke J, Steiger BW, Muscoplat C, Gallagher SC. A multi-center, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-1131.
64. Ferguson MM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1993;75:186-189.
65. Rhodus NL, Young L, Lindemann K, Rudney J, Mathur A, Bereuter J. Salivary s-IgA and cytokine levels in Sjögren's patients before and after pilocarpine HCl administration. J Clin Invest 1999;2:1-5.
66. Fox PC. Management of dry mouth. Dent Clin North Am 1997;41:863-876.
67. Vivino F, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury P, Tran-Johnson TK, Trivedi M, Goldlust B, Gallagher S, Muscoplat C, Rhodus NL. A double-blind, fixed dose, placebo-controlled study of pilocarpine HCl tablets for the treatment of symptoms related to Sjögren's syndrome. Arch Intern Med 1999;159:174-181.
68. Fox PC, Atkinson JC, Macynski AA. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991;151:1149-1153.
69. Ferguson MM, Hayes P, Highton J, Jones DS, MacFayden EE, Palmer DG. Pilocarpine oral solution. Br J Dent 1991; 170:251.
70. Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M. Treatment of radiation side effects with pilocarpine. J Surg Oncol 1989;42:272-276.
71. Dawes C. Factors influencing salivary flow rate and composition. In: Edgar WM, O'Mullane DM (eds). Saliva and Oral Health. London: British Dental Association, 1996:31.
72. Everett HC. The use of bethanachol chloride with tricyclic antidepressants. Am J Psychiatry 1975;136:110-111.
73. Teichman SL, Ferrick A, Kim SG, Matos JA, Waspe LE, Fischer JD. Disopyramide-pyradostigmine interaction: Selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J Am Coll Cardiol 1987;10: 633-641.
74. Epstein J, Decoteau WE, Wilkenson W. Effect of Sialor in the treatment of xerostomia in Sjögren's syndrome. Oral Surg Oral Med Oral Pathol 1983;56:495-499.
75. Ship J, Fox P, Michalek JE, Cummins M, Richards AB, Rhodus NL. Human IFN-alpha for the treatment of Sjögren's syndrome. J Cytokine Res 1999 (in press).
76. Talal N, Quinn JH, Daniels TE. The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. J Rheumatol 1992;12:43-45.
77. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology 1986;5:75-99.